Aspirin Demonstrates Cost Benefit Versus Statins In Heart Disease – Study
This article was originally published in The Tan Sheet
Executive Summary
Aspirin use for coronary heart disease prevention in a patient with a 5% five-year coronary risk costs less than one-fifth per event prevented than simvastatin (J&J/Merck's Zocor) in a patient at a 30% five-year risk, a British study found
You may also be interested in...
Aspirin cost-effectiveness
Increased use of aspirin for secondary prevention of coronary heart disease "is attractive from a cost-effectiveness perspective," while treatment with Rx clopidogrel "is currently unattractive" due to its high price, according to June 6 NEJM. Jean-Michel Gaspoz, MD, et al., Hopitaux Universitaires, Geneva, estimated incremental cost effectiveness from 2003-2007 of four strategies in CHD patients over 35. Researchers found extension of aspirin therapy from current levels of use to all eligible patients "would have an estimated cost-effectiveness ratio of about $11,000 per quality-adjusted year of life gained." Clopidogrel alone would have incremental cost of over $130,000, researchers say...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands